Search

Your search keyword '"Bellecave P"' showing total 116 results

Search Constraints

Start Over You searched for: Author "Bellecave P" Remove constraint Author: "Bellecave P"
116 results on '"Bellecave P"'

Search Results

1. Atorvastatin and telmisartan do not reduce nasopharyngeal carriage of SARS-CoV-2 in mild or moderate COVID-19 in a phase IIb randomized controlled trial

3. External validation of the PAGE-B score for HCC risk prediction in people living with HIV/HBV coinfection

4. One year of SARS-CoV-2 circulation in the Nouvelle-Aquitaine region, February 2021–2022, France

5. Impact of Human Immunodeficiency Virus Type 1 Minority Variants on the Virus Response to a Rilpivirine-Based First-line Regimen

6. Impact of the mutational load on the virological response to a first-line rilpivirine-based regimen.

7. Trends in mortality in people with HIV from 1999 to 2020: a multi-cohort collaboration

8. Cross-resistance to elvitegravir and dolutegravir in 502 patients failing on raltegravir: a French national study of raltegravir-experienced HIV-1-infected patients

9. Antiretroviral-naive and -treated HIV-1 patients can harbour more resistant viruses in CSF than in plasma

10. Risk for non-AIDS-defining and AIDS-defining cancer of early versus delayed initiation of antiretroviral therapy

11. GCN2 phosphorylates HIV-1 integrase and decreases HIV-1 replication by limiting viral integration

12. Provir/Latitude 45 study: A step towards a multi-epitopic CTL vaccine designed on archived HIV-1 DNA and according to dominant HLA I alleles.

13. Contribution of APOBEC3G/F activity to the development of low-abundance drug-resistant human immunodeficiency virus type 1 variants

14. Equivalent configurations for notch and fretting fatigue

15. Depressive symptoms after hepatitis C cure and socio-behavioral correlates in aging people living with HIV (ANRS CO13 HEPAVIH)

16. Risk for non-AIDS-defining and AIDS-defining cancer of early versus delayed initiation of antiretroviral therapy: A multinational prospective cohort study

17. Sanger and Next-Generation Sequencing data for characterization of CTL epitopes in archived HIV-1 proviral DNA.

18. Post‐HCV cure self‐reported changes in physical activity, eating behaviours, and fatigue in people living with HIV (ANRS CO13 HEPAVIH)

19. HIV-1 Coreceptor Usage Assessment by Ultra-Deep Pyrosequencing and Response to Maraviroc.

20. Tobacco, alcohol, cannabis, and illicit drug use and their association with CD4/CD8 cell count ratio in people with controlled HIV: a cross-sectional study (ANRS CO3 AQUIVIH-NA-QuAliV).

21. Gender differences in the use of cardiovascular interventions in HIV‐positive persons; the D:A:D Study

22. HIV-1 subtype B-infected MSM may have driven the spread of transmitted resistant strains in France in 2007–12: impact on susceptibility to first-line strategies

23. Virological failure of patients on maraviroc-based antiretroviral therapy

24. Prevalence and evolution of low frequency HIV drug resistance mutations detected by ultra deep sequencing in patients experiencing first line antiretroviral therapy failure.

25. Kinetics of HIV-1 CTL epitopes recognized by HLA I alleles in HIV-infected individuals at times near primary infection: the Provir/Latitude45 study.

26. Molecular characterization of HIV-1 CRF01_AE in Mekong Delta, Vietnam, and impact of T-cell epitope mutations on HLA recognition (ANRS 12159).

27. National sentinel surveillance of transmitted drug resistance in antiretroviral-naive chronically HIV-infected patients in France over a decade: 2001–2011

28. Patient-reported symptoms during direct-acting antiviral treatment: A real-life study in HIV-HCV coinfected patients (ANRS CO13 HEPAVIH)

29. Surveillance of HIV-1 primary infections in France from 2014 to 2016: toward stable resistance, but higher diversity, clustering and virulence?

30. Impact of the M184V/I Mutation on the Efficacy of Abacavir/Lamivudina/Dolutegravir Therapy in Human Immunodeficiency Virus Treatment-Experienced Patients

31. Erratum: Impact of the M184V/I mutation on the efficacy of abacavir/lamivudine/dolutegravir therapy in HIV treatment-experienced patients (Open Forum Infectious Diseases (2019) 6: 10 (ofz330) DOI: 10.1093/ofid/ofz330)

32. Impact of the M184V/I Mutation on the Efficacy of Abacavir/Lamivudine/Dolutegravir Therapy in HIV Treatment-Experienced Patients

33. Impact of the M184V/I Mutation on the Efficacy of Abacavir/Lamivudine/Dolutegravir Therapy in HIV Treatment-Experienced Patients

35. Impact of Human Immunodeficiency Virus Type 1 Minority Variants on the Virus Response to a Rilpivirine-Based First-line Regimen

36. Antiretroviral-naive and -treated HIV-1 patients can harbour more resistant viruses in CSF than in plasma

37. Contribution of APOBEC3G/F activity to the development of low-abundance drug-resistant human immunodeficiency virus type I variants

38. Contribution of APOBEC3G/F activity to the development of low-abundance drug-resistant human immunodeficiency virus type 1 variants

39. GCN2 phosphorylates HIV-1 integrase and decreases HIV-1 replication by limiting viral integration

40. Antiretroviral-naive and -treated HIV-1 patients can harbour more resistant viruses in CSF than in plasma

41. Contribution of APOBEC3G/F activity to the development of low-abundance drug-resistant human immunodeficiency virus type I variants

42. Contribution of APOBEC3G/F activity to the development of low-abundance drug-resistant human immunodeficiency virus type 1 variants

43. A New HIV-1 Circulating Recombinant Form (CRF98_cpx) Between CRF06_cpx and Subtype B Identified in Southwestern France.

44. Therapeutic Vaccine Against HIV, Viral Variability, Cytotoxic T Lymphocyte Epitopes, and Genetics of Patients.

49. Evaluation of Automatic Analysis of Ultradeep Pyrosequencing Raw Data to Determine Percentages of HIV Resistance Mutations in Patients Followed-Up in Hospital.

50. Diversity of HIV-1 in Acquitaine, Southwestern France, 2012–2016.

Catalog

Books, media, physical & digital resources